A Study of LY3867070 in Healthy Participants

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Sep 2026 to Oct 2026
  2. Enrollment closed, study ongoing
    • Primary and study completion dates: Aug 2026 to Sep 2026
    • Eligibility criteria expanded, about 9 words
    • Site details revised at 2 of 2 sites
  3. Site details revised at 1 of 2 sitesv9
  4. Trial arms changed: 6 → 5v8
  5. Site contacts updated at 1 of 2 sitesv7
Show 5 earlier versionsHide 5 earlier versions
  1. Site contacts updated at 1 of 2 sitesv6
  2. Site contacts updated at 1 of 2 sitesv5
  3. 2 versions Re-verified since Sep 24, 2025, no change to tracked fieldsv3-v4
  4. Eligibility criteria shortened, about 92 words
    • Secondary endpoints revised (3)
    v2
  1. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
366 trials monitored
See 16 trials at risk
The purpose of this study is to evaluate how well LY3867070 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Trial Details
NCT Number NCT07021547
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Healthy
Enrollment 196 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov